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Abstract
This study investigated the in vivo properties of two heavy chain antibody fragments (VHH), ni3A and pa2H, to differentially
detect vascular or parenchymal amyloid-b deposits characteristic for Alzheimer’s disease and cerebral amyloid angiopathy.
Blood clearance and biodistribution including brain uptake were assessed by bolus injection of radiolabeled VHH in APP/PS1
mice or wildtype littermates. In addition, in vivo specificity for Ab was examined in more detail with fluorescently labeled
VHH by circumventing the blood-brain barrier via direct application or intracarotid co-injection with mannitol. All VHH
showed rapid renal clearance (10–20 min). Twenty-four hours post-injection
99mTc-pa2H resulted in a small yet significant
higher cerebral uptake in the APP/PS1 animals. No difference in brain uptake were observed for
99mTc-ni3A or DTPA(
111In)-
pa2H, which lacked additional peptide tags to investigate further clinical applicability. In vivo specificity for Ab was
confirmed for both fluorescently labeled VHH, where pa2H remained readily detectable for 24 hours or more after injection.
Furthermore, both VHH showed affinity for parenchymal and vascular deposits, this in contrast to human tissue, where ni3A
specifically targeted only vascular Ab. Despite a brain uptake that is as yet too low for in vivo imaging, this study provides
evidence that VHH detect Ab deposits in vivo, with high selectivity and favorable in vivo characteristics, making them
promising tools for further development as diagnostic agents for the distinctive detection of different Ab deposits.
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Introduction
Besides neurofibrillary tangles, Alzheimer’s disease (AD) is
characterized by cerebral deposition of b-amyloid (Ab) in so-called
senile or diffuse plaques [1]. Similar vascular deposits of Ab
associated with cerebral amyloid angiopathy (CAA) lead to loss of
vessel wall integrity increasing the risk of brain haemorrhages [2].
Present in 30% of the non-demented population over 60 years of
age, CAA co-exists in 90% of the AD patients and forms an
important complication in the development of immunotherapeutic
strategies [3–5]. Although, the exact role of Ab regarding the
underlying pathogeneses remains unsolved, accumulation is
believed to start 20–30 years prior to clinical onset [6,7].
Distinctive in vivo detection of the different Ab deposits therefore
renders important knowledge regarding early diagnosis and
preventive therapy development.
Currently, a gross differentiation can only be made based on the
occipital predilection of CAA, while existing PET ligands, like
11C-
PiB, target Ab in its fibrillar amyloid form rather than specific
vascular or parenchymal types of Ab deposits [8].
Previously, we have selected heavy chain antibody fragments
with high affinity specific for either CAA or all types of human Ab
deposits [9]. Derived from the Camelid heavy chain antibody
repertoire, which completely lack light chains, their single N-
terminal domain (VHH) is fully capable of antigen binding with
affinities comparable with those of conventional antibodies
[10,11].
Blood-brain barrier (BBB) passage was shown to be favorable in
an in vitro assay [12]; therefore, this study assessed the in vivo
characteristics of two distinct Ab targeting VHH, ni3A and pa2H,
for their potential use to differentially detect AD and CAA. First,
pharmacologic behaviour and biodistribution were examined after
administration of radiolabeled VHH into a transgenic AD/CAA
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istered after the BBB was circumvented to evaluate their ability to
specifically bind Ab deposits in vivo.
Materials and Methods
Production of ni3A and pa2H
VHH ni3A and pa2H were selected from respectively a non-
immune or an immune library created after immunisation with
post-mortem brain parenchyma of a patient with Down’s
syndrome. VHH were subcloned and produced as previously
reported including a myc- or VSV-tag for detection and a his-tag
for purification [9]. Similarly, pa2H free of any additional peptide
tags was commercially produced by overexpression in yeast (BAC,
Leiden, the Netherlands).
Animal studies
All studies were performed using 12–16 month old transgenic
mice or wildtype littermates from a colony set up using the
APPswe/PS1dE9 strain (APP/PS1) (JAX), known to accumulate
vascular and parenchymal Ab deposits [13], and have been
approved by the institutional Animal Ethics Committee (DEC) at
the Leiden University Medical Center, permit number 09132.
Besides standard genotyping, after each experiment amyloid
pathology was confirmed by standard Thioflavin T staining.
Human material
Human brain tissue was obtained of AD/CAA patients or
controls as confirmed by neuropathological examination in
agreement with the guidelines of the ethics committee of the
LUMC. Patient anonymity was strictly maintained. All tissue
samples were handled in a coded fashion, according to Dutch
national ethical guidelines (Code for Proper Secondary Use of
Human Tissue, Dutch Federation of Medical Scientific Societies).
Murine specificity of the selected VHH
To evaluate appropriate use of the APP/PS1 mouse model,
murine cryosections (10 mm) were stained according previous
protocols [9,12] with in addition a standard anti-mouse-to-mouse
kit (ARK, Dako Cytomation). Final preparations were analyzed
with an automated Pannoramic MIDI microscope (3DHistech).
Biodistribution and clearance
Radiolabeling. VHH were labeled according to two different
protocols. First, his-tagged VHH were labeled directly with
technetium-99m (
99mTc) using a previously published protocol
[14]. Briefly, 20 mlo fV HH in PBS solution (450–500 ng/ml) was
added to 8 ml of an aseptic mixture of 950 mg/l Sn(Cl)2.2H2O and
2 g/l Na4P2O7.10H2O (Technescan PYP, Covidien, Petten, the
Netherlands) in saline. After addition of 4 ml of 10 mg/ml of
KBH4 (crystalline, Sigma Chemical Co, St. Louis, MO) in 0.1 M
NaOH, and 100 ml of Na[
99mTcO4] solution (approximately 200–
700 MBq/ml, Technekow, Covidien, Petten, the Netherlands) the
mixture was gently stirred at room temperature for at least 30 min
before use. Analysis of the labeling solution, referred to as
99mTc-
VHH, yielded a radiochemical purity of .95% without detectable
unreduced or free
99mTcO4 [15].
Secondly, untagged VHH were chelated for indium-111 (
111In)
using diethylene triamine penta-acetic acid (DTPA). Untagged
pa2H was chelated in a total volume of 1.0 ml with 20-fold
molecular excess of p-SCN-Bn-DTPA (Macrocyclics, Dallas, TX)
at pH 8.5 in phosphate buffer for 5 hr at 37.5uC and purified by
dialysis using phosphate buffered saline (PBS).
111In chloride
(25 ml, 111 MBq/ml, Covidien, the Netherlands) was added to
DTPA-pa2H conjugate (0.1 ml) in 0.25 M ammonium acetate
buffer (0.8 ml) at pH 5.5 and incubated for 1 hr at room
temperature. The reaction was quenched with 50 mM ethylene
diamine tetra-acetic acid (EDTA) (50 ml) to chelate residual non-
bound
111In and the radiolabeled antibody was then purified using
Figure 1. Immunostaining on murine APP/PS1 sections using ni3A and pa2H. The upper panels (A–D) show 106magnifications of the
resulting staining with cryosections of aged APP/PS1 mouse brain tissue including negative controls, while the lower panels (E–H) show similar
staining performed with wildtype littermates.
doi:10.1371/journal.pone.0038284.g001
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TM G-25 column (PD 10; GE Healthcare) eluted with
PBS. Radiochemical purity assessed by instant thin layer
chromatography (ITLC) yielded a purity of .95%.
Biodistribution and brain uptake. To study the biodis-
tribution, animals were injected intravenously with 0.2 ml
radiolabeled VHH diluted with saline (5–10 MBq/ml, 10 mg/
ml). At different intervals (t=3–6–24 hrs) post-injection APP/PS1
(n=4) and wildtype animals (n=4) were sacrificed (Euthanasol,
AST Pharma). Similar biodistribution experiments using untagged
DTPA(
111In)-pa2H were only performed at 24 hours post-
injection for APP/PS1 (n=6) and wildtype mice (n=6). Blood
was collected via cardiac puncture, and various organs were
removed, including the brain, which was divided into the
cerebrum and cerebellum. All were weighed and counted for
radioactivity (Wizard
2, Perkin Elmer). After decay correction,
radioactivity was expressed as the percentage of the total injected
dose of radioactivity per gram tissue (%ID/g). Blood/cerebrum
ratios were calculated to correct for possible confounding effects
accountable by residual blood. Similarly, muscle/cerebrum
determined target-to-non-target ratios. Differences were regarded
significant when p#0.05 using an unpaired one or two tailed t-test.
Experiments at t=24 hrs were repeated twice using
99mTc-pa2H.
Blood clearance and analysis. Simultaneously, blood half-
life was examined by collecting 5 ml tail samples at several time
Table 1. Biodistribution of
99mTc-ni3A in mice.
t=3 hr t=6 hr t=24 hr
Tissue/organ Wildtypes APP/PS1 Wildtypes APP/PS1 Wildtypes APP/PS1
blood 1.20260.379 1.14660.131 0.77860.048 0.80860.115 0.45160.073 0.36360.051
heart 0.52560.129 0.50860.109 0.34760.049 0.33760.127 0.25260.041 0.21660.014
lungs 0.85060.184 0.81960.208 0.65960.184 0.74360.301 0.37560.113 0.29160.055
liver 1.07860.235 1.00060.293 1.07860.188 1.22360.424 0.56860.149 0.48860.164
kidneys 15.53162.986 15.19263.075 10.26661.657 14.29464.337 9.08966.152 9.90161.158
spleen 0.59060.257 0.53160.084 0.79260.144 0.75360.291 0.39760.056 0.46560.234
muscle 0.17160.075 0.12060.069 0.11160.088 0.08660.022 0.04360.007 0.04860.008
cerebrum 0.03560.009 0.03560.007 0.03160.007 0.03560.008 0.01860.003 0.01960.001
cerebellum 0.07360.031 0.06360.009 0.09860.009 0.09660.014 0.02960.005 0.02660.002
cerebrum/blood ratio 0.03060.003 0.03060.004 0.04060.010 0.04360.004 0.04060.001 0.05360.008*
cerebrum/muscle ratio 0.24260.142 0.33560.116 0.40760.270 0.42860.171 0.42260.029 0.40360.100
*=P,0.05 wildtype mice compared to APP/PS1 mice.
A bolus injection of 2 mg
99mTc-ni3A was administered intravenously into 12–14 month old APP/PS1 mice or their wild type littermates. At three time points after
injection the animals were sacrificed and various tissues and entire organs were removed, weighed and counted for radioactivity. Values are expressed as a percentage
of the injected dose per gram tissue (mean 6 SD).
doi:10.1371/journal.pone.0038284.t001
Table 2. Biodistribution of radiolabeled pa2H in mice.
99mTc-pa2H DTPA(
111In)-pa2H
t=3 hr t=6 hr t=24 hr t=24 hr
Tissue/organ Wildtypes APP/PS1 Wildtypes APP/PS1 Wildtypes APP/PS1 Wildtypes APP/PS1
blood 0.56660.003 0.65460.015 1.00960.054 1.24460.123 0.57560.084 0.69660.049 0.00660.001 0.00460.002
heart 0.27360.121 0.24060.017 0.62360.101 0.76360.031 0.36760.059 0.39360.007 0.01760.084 0.01460.003
lungs 0.84360.256 0.53760.010 0.93060.242 1.08860.035 0.62060.160 0.62260.031 0.01660.011 0.01460.003
liver 2.61560.796 1.86660.016 3.01461.021 3.39261.932 1.43060.402 1.16160.470 0.06660.029 0.07560.0.23
kidneys 9.24361.787 6.24160.530 14.30664.105 15.61261.042 9.82462.810 8.60860.738 8.85963.623 7.68962.930
spleen 1.51560.503 1.31960.060 6.49861.623 6.25860.208 3.58461.381 1.74760.100 0.04460.022 0.04860.006
muscle 0.35660.379 0.05460.006 0.17460.022 0.34760.026 0.10260.023 0.11360.018 0.05960.020 0.05960.044
cerebrum 0.01460.003 0.01760.001 0.03360.005 0.04460.004 0.02760.004 0.03860.002* 0.00160.000 0.00160.001
cerebellum 0.02360.001 0.02660.001 0.05460.016 0.06760.001 0.03060.007 0.04560.000* 0.00360.001 0.00260.001
cerebrum/blood ratio 0.02560.005 0.02660.003 0.03360.004 0.03560.004 0.04760.003 0.05560.008 0.01360.011 0.04160.055
cerebrum/muscle ratio 0.08360.081 0.30960.067 0.19060.007 0.17760.135 0.27060.032 0.34660.377 0.11360.066 0.20360.146
*=P,0.05 wildtype mice compared to APP/PS1 mice.
A bolus injection of 2 mg radiolabeled pa2H was administered intravenously into 12–14 month old APP/PS1 mice or their wildtype littermates. At three or one time
points after injection of radiolabeled pa2H respectively with or without additional peptide tags, the animals were sacrificed and various tissues and entire organs were
removed, weighed and counted for radioactivity. Values are expressed as a percentage of the injected dose per gram tissue (mean 6 SD).
doi:10.1371/journal.pone.0038284.t002
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into transgenic or wildtype mice (n=4–6). Combined with the
cardiac blood samples corresponding half-lives were calculated
using GraphPad Prism.
Similarly, 10 ml samples obtained at 10 and 90 minutes post-
injection were mixed with 90 ml heparin (34 U/ml saline) and
900 ml PBS. Centrifugation for 10 minutes at 7,000 rpm separated
plasma from the cell pellet. Radioactivity was measured separately
to determine the blood distribution of radiolabeled VHH over
time.
Specificity of radiolabeled pa2H. Ab specificity of pa2H-
his after
99mTc-radiolabeling was tested by quantitative competi-
tion autoradiography. Human and murine brain cryosections
(20 mm) were blocked with 1% bovine serum albumin (BSA)/PBS
at 37uC for 1 hour followed by similar application of the labeling
solution, which was diluted to 1 mg/ml by 1%BSA/PBS with or
without additional 1 hour pre-incubation with excess monomeric
or fibrillar Ab1–40 (rPeptide) at 37uC. Fibrils were produced using
existing protocols [16].
After rinsing 3 times with PBS, radioactivity was counted for
15 minutes by a gamma camera (Toshiba GCA7100/UI). A
similar region of interest was fitted for each scintigram to assess
binding of
99mTc-pa2H-his with 0.1 ml of diluted labeling solution
as a reference. Binding was expressed as the % of radioactivity
compared to the section without any competitor. Experiments
were performed in triplicate.
In vivo Ab targeting by VHH
Fluorescent labeling. Tagged VHH were fluorescently
labeled with Alexa Fluor 594 protein labeling kit (Molecular
Probes, Invitrogen) according to the manufacturer’s guidelines,
except using only half of the recommended amount of dye. Briefly
spun to remove possible aggregates, extensive dialysis removed
Figure 2. Blood clearance. These graphs represent the blood half lives of tagged
99mTc-ni3A and -pa2H (A), and untagged DTPA(
111In)-pa2H (B)i n
APP/PS1 mice and wildtype littermates. Data is shown as percentage of injected dose per gram of blood (%ID/g) over time. Based upon this plot the
clearance is suggested to respectively consist of a fast and a slow phase, or only a single phase.
doi:10.1371/journal.pone.0038284.g002
Table 3. Blood half lives of radiolabeled VHH.
Fast tK Slow tK
VHH genotype (min) (95% C.I.)% (min) % (95% C.I.)
99mTc-ni3A APP/PS1 14.71 (8.65–
49.13)
89.7 580 10.3 (101.8–‘)
Wildtype ND ND ND ND
99mTc-pa2H APP/PS1 21.89 (14.24–
39.38)
79.8 2562 20.2 (975.0–‘)
Wildtype 10.78 (7.27–
20.76)
87.1 5861 12.9 (969.3–‘)
DTPA(
111In)-
pa2H
APP/PS1 19.69 12.63–
44.60
100 - -
Wildtype 15.83 9.30–
53.37
100 - -
Half lives were determined by fitting a one or a two phase exponential decay
model based on blood obtained from both tail vein and cardiac puncture at
several time points after intravenous bolus injection of 2 mg radiolabeled VHHi n
12–14 month old APP/PS1 mice and wildtype littermates, as depicted in
Figure 2. Please note that DTPA(
111In)-pa2H was produced without any
additional peptide tags.
doi:10.1371/journal.pone.0038284.t003
Table 4. Blood distribution of
99mTc-pa2H.
Sample Time p.i. Fraction APP/PS1 Wildtype
(min) (%) sd (%) sd
99mTc-pa2H 10 Plasma 88,9 6,2 80,3 5,2
Cell Pellet 11,1 19,7
90 Plasma 83,6 8,7 72,0 8,2
Cell Pellet 16,4 28,0
At different time point after bolus injection of
99mTc-pa2H blood collected from
the tail vein of 12–14 month old APP/PS1 mice or wildtype littermates.
Separated into the cell pellet and plasma, samples were counted for
radioactivity. Fractions are expressed in percentage of total activity at that time
point. No significant differences were calculated using a student t-test (p,0.05).
doi:10.1371/journal.pone.0038284.t004
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(200–600 ng/ml) were determined using the Nanodrop ND1000
(Isogen Life Sciences). Protein integrity was confirmed by mass
spectrometry.
Immunofluorescence using VHH-Alexa594. To examine
whether the fluorescent labeling affected antigen recognition,
human and murine cryosections (10 mm) were rinsed with PBS,
fixed in ice-cold acetone for 10 minutes before overnight
incubation with VHH- Alexa594 in 1% BSA/PBS in a wet
chamber. Washed 365 minutes with PBS, sections were mounted
and analyzed using a fluorescence microscope (Leica
DMR5500B).
In vivo Ab imaging by topical application. Four APP/PS1
animals received permanent cranial windows to allow serial in vivo
imaging of the brain by multiphoton microscopy. Animals were
anaesthetized using 2% isoflurane gas inhalation, and the exposed
skull was partly replaced by a round glass coverslip glued into
place using KrazyglueH according to previous surgical protocols
[17,18]. Prior to fixation of the cranial window, a drop of 40–60 ml
of VHH-Alexa594 (275–400 ng/ml) was applied directly onto the
exposed brain for 30 minutes and briefly rinsed with PBS.
Colocalization with the Ab deposits was based either upon their
typical green autofluorescence or by intraperitoneal injections of
Methoxy-X04 one day prior surgery [16]. Animals were imaged
immediately following surgery, which was typically less than
90 minutes after beginning of the procedure, and re-imaged under
isoflurane anaethesia (2%) for several days to study the washout.
Images were acquired with a Bio-Rad 1024 multiphoton
microscope equipped with a Ti:Sapphire laser (Mai Tai, Spectra
Physics) and external photodetectors (Hamamatsu Photonics).
Areas were imaged to approximately 200 mm deep in 5 mm steps
with a 206 objective (UMPlanFl, NA=0.95; Olympus). Maxi-
mum intensity projections were reconstructed using ImageJ.
Specific in vivo Ab binding after BBB disruption. A
systemic approach to study the in vivo behaviour of the VHH
throughout a larger area within the brain involved intracarotid
infusion (60 ml/min) of 100 ml pa2H-his-Alexa594 along with
600 ml 15% mannitol selectively into the right carotic artery to
disrupt the BBB [19]. At t=2 and 24 hours post-injection.,
transgenic (n=9) and wildtype animals (n=3) were euthanized
(Euthanasol, AST Pharma), and perfused with 4% paraformalde-
hyde (PFA). Resected brains were stored in 4% PFA with 10%
sucrose for 4 hours followed by overnight fixation in 4% PFA with
30% sucrose. Next, the brains were snap frozen and sectioned
completely to obtain consecutive 30-mm-thick cryosections.
Besides standard Thioflavin T staining for amyloid, adjacent
sections were immunostained for Ab (6F/3D, DakoCytomation)
[20] with 1:100 goat-antimouse-Alexa488 (Invitrogen) to assess
colocalization. Images obtained by a Leica DM5500B microscope
were merged using Adobe Photoshop CS3.
Results
Murine specificity of the selected VHH
Immunostained brain sections of aged APP/PS1 and wildtype
littermates using tagged VHH ni3A and pa2H were made to assess
their capacity to selectively recognize different types of deposits.
(Figure 1) Pa2H stained positive for all forms of Ab depositions. In
this transgenic mouse model, ni3A did not show selective affinity
for vascular Ab; both vascular and parenchymal Ab depositions
were clearly labeled. Compared to ni3A, equivalent staining
protocols with pa2H resulted in higher specificity for Ab combined
with a low unspecific background binding. For neither VHH
specific affinity was detected within the brain sections of wildtype
animals.
Biodistribution and clearance
Biodistribution and brain uptake. The distribution of a
bolus injection of radiolabeled tagged ni3A and pa2H over time is
shown in Table 1 and 2. No significant differences in organ uptake
between wildtype and transgenic animals were found, except for
the brain uptake of
99mTc-pa2H after 24 hours. Although the
amount was low (0.038%I.D./g), cerebral uptake was 40% higher
in the transgenic animals. The cerebrum/blood ratio did not
differ, indicating that this difference was not caused by different
VHH concentrations within the blood pool. For the cerebellum
similar results were found. Repeated experiments for this
particular endpoint resulted in similar findings.
To investigate whether these findings were not confounded by
either the non-specific radiolabeling procedure or the presence of
additional peptide tags, the biodistribution experiment was
repeated with untagged DTPA(
111In)-pa2H. (Table 2) With this
labeling protocol, we no longer observed a significantly higher
cerebral uptake in amyloid-bearing mice. Regardless of the tag,
the majority of radiolabeled VHH was excreted via the kidneys.
Cellular involvement as shown by distinctive hepatic clearance or
splenal activity was low. In comparison to
99mTc-ni3A,
99mTc-
pa2H showed about 3 times higher clearance via liver and spleen.
Also, the clearance rate for
99mTc-pa2H was lower, independent
of genotype. However, within the first 3 hours
99mTc-ni3A
resulted in a higher general organ uptake, with exception of the
aforementioned liver and spleen.
Blood clearance and analysis. Blood clearance of the
tagged
99mTc-VHH consisted of a fast and a slow component.
(Figure 2A) In general, the majority of the radiolabeled VHH was
cleared from the blood with a half-life of 10–20 minutes (Table 3).
The actual half-life of the slow component of
99mTc- VHH could
only be calculated with limited accuracy, since the half-life was
longer than the blood sampling period. In line with the above
biodistribution, six hours post-injection, the blood levels of
99mTc-
pa2H were remarkably higher compared to earlier time points,
which is characteristic for a second passage. Within the first
90 minutes about 80% of the
99mTc-VHH remained within the
blood plasma, indicating that no significant cellular uptake
occurred. (Table 4)
In contrast to tagged
99mTc- VHH, the blood clearance of
untagged DTPA(
111In)-pa2H was mono-exponential, with a
similar rapid clearance within 20 minutes, but without a slow
component. (Figure 2B)
Table 5. Quantitative autoradiography.
Brain tissue
Binding of
99m
Tc-VHH Competion binding
Monomeric Ab Fibrillar Ab
ng (± sd) ng (± sd) ng (± sd)
APP/PS1 98.8 (620,7)* 60.1 (622.2) 31.4 (614.3)
Wildtype 86.4 (614.8) 56.4 (619.5) 27.1 (612.5)
AD human 190.1 (673.5)* 81.4 (6 N.D.) 42.3 (629.2)
Control human 102.3 (630.2) 27.2 (6 N.D.) 49.9 (617.4)
Differences in radioactivity were measured after application of 1 mg
99mTc-pa2H
to human and murine APP/PS1 brain sections.
*Statistical difference (p,0.05) between either murine or human control versus
Ab bearing sections.
doi:10.1371/journal.pone.0038284.t005
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tagged pa2H it’s specificity for Ab was unaffected, as shown by
scintigraphic analysis; binding of
99mTc-pa2H was higher in those
sections including Ab. (Table 5) Furthermore, binding was
significantly (p,0.001) reduced when the tracer was pre-incubated
with either monomeric or fibrillar Ab.
In vivo Ab targeting by VHH
In vivo Ab imaging by topical application. After direct
application onto the exposed mouse brain, fluorescent VHH were
followed up for at least 48 hours by in vivo multiphoton
microscopy. (Figure 3) Specific in vivo labeling of Ab plaques by
ni3A-Alexa594 was initially confirmed by colocalization with
Methoxy-X04, a known in vivo amyloid targeting fluorophore.
Beside possible binding competition with the VHH, Methoxy-X04
hampered good validation due to signal cross-over into the red
channel. However, colocalization based on the typical autofluo-
rescence patterns of the different Ab deposits resulted in similar
findings. Selectivity was confirmed by lack of nonspecific
background signal. Although both VHH were capable of targeting
Ab in vivo, only pa2H-Alexa594 was detectable after two days,
mainly bound to vascular amyloid.
Specific in vivo Ab binding after BBB disruption. Based
on the above findings, co-injections of pa2H-Alexa594 with
mannitol were done in the right carotid artery to selectively open
the BBB in the ipsilateral hemisphere to study the in vivo
characteristics throughout the brain. Two hours post-injection,
fluorescence was detected in the right hemisphere, co-localizing
with Ab. (Figure 4) Even within the deeper brain structures, no
nonspecific binding was observed. Ab related fluorescent signal
remained detectable for at least 24 hours post-injection. Without
BBB disruption or within wildtype littermates, no apparent Ab
labeling could be detected.
Immunofluorescence using VHH-Alexa594. Selectivity for
specific Ab deposits was not altered after fluorescent labeling of the
VHH, since on human sections, ni3A-Alexa594 selectively stained
vascular Ab (Figure 5 A–C), and pa2H-Alexa594 stained both
parenchymal and vascular Ab.(Figure 5 G–I) On murine material
all Ab deposits were stained by both fluorescent VHH.(Figure 5
D–F & J–L)
Discussion
In this study, we assessed two previously described VHH for
their potential to cross the blood-brain barrier and distinctively
detect vascular and parenchymal Ab deposits in vivo.
Specific detection of parenchymal and vascular amyloid
in APP/PS1 mice
Both VHH stained positive for Ab upon APP/PS1 brain sections
confirming appropriate use of this transgenic model. In vivo
binding to parenchymal and vascular Ab was confirmed when the
BBB was circumvented. Signal remained detectable for at least
24 hours while in vivo pa2H showed a high affinity combined with
a low off-rate. However, previously shown selectivity for solely
vascular Ab in human post-mortem brain sections by ni3A was not
Figure 3. In vivo Ab imaging after direct brain application. Topical application of ni3A- or pa2H-Alexa594 (red) as visualized over time by
intravital multiphoton microscopy in APP/PS1 mice clearly shows the specific in vivo labeling of different Ab deposits. In the left, vascular and
parenchymal Ab deposits, detected by prior labeling with Methoxy-X04 (blue), colocalize with ni3A-Alexa594 (red) directly following topical
application. One day later, labeling of the plaques has diminished to almost none with some residual left bound to CAA. With interpretation
hampered by Methoxy-X04, middle images show a similar experiment. Colocalization with Ab deposits based upon autofluorescence (green) gave
comparable results and almost complete wash out after two days. Pa2H-Alexa594 (red), as shown in the right images, remains bound to vascular Ab
even two days after application, when the plaques remained undetected. All images are maximum intensity projections of a 3D cortical volume with
a field of view 6156615 mm.
doi:10.1371/journal.pone.0038284.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38284Figure 4. Specific in vivo Ab binding after BBB disruption. After disruption of the BBB using a co-injection of 15% mannitol with pa2H-
Alexa594 into the right carotid artery of an aged APP/PS1 mouse sacrificed 2 hrs post injection, amyloid plaques are clearly depicted in both
hemispheres using a Thioflavin T (ThT) staining (A), while the pa2H-Alexa594 signal is only detected in the right hemisphere (B). More careful
examination shows all Alexa594 signal colocalizes with ThT in the right hemisphere, while in the left only some autofluorescense can be detected.
Furthermore, immunofluorescense anti-Ab staining of the plaques using Alexa488 within the left hemisphere (C) results only in green signal, while
within the right hemisphere (D) the red signal from pa2H-Alexa594 nicely colocalizes within the plaques. Experiments performed in a similar setting
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radiolabeling prior in vivo application did not affect their specificity.
The unique specific reactivity of ni3A for vascular amyloid
deposition on human brain material is not yet completely
understood [9]. Known differences in morphology and composi-
tion of human and murine Ab deposits might help to understand
ni3A’s specific reactivity [21,22]. Human plaques consist of
discontinuous patches with decreased density and random fibrillar
orientation within the amyloid core; murine plaques are generally
built up by long organized fibrils, resulting in densely packed
amyloid plaques with a relatively large core [23]. Besides
morphological differences, posttranslational modifications of Ab
differ from mouse to man leading to alterations of the Ab molecule
itself [21,24,25]. Differences in metal ion content are known to
influence the tertiary structure [26,27]. Previous epitope mapping
revealed that ni3A has no other cross reaction but to Ab1–42 [9],
which is highly abundant in parenchymal and vascular deposits in
both humans and APP/PS1 mice. All together, this leads to the
conclusion that the selective reactivity of ni3A must depend on the
structural presentation of Ab1–42, in which case murine paren-
chymal plaques probably show structural similarities to human
CAA.
In vivo blood-brain barrier passage
Previous in vitro data suggested that our VHH actively migrated
across the BBB in a more efficient way than FC5, a VHH
specifically selected to pass the BBB [12]. However, the in vivo
experiments resulted only in a small cerebral uptake of the tagged
99mTc-pa2H at 24 hours after intravenous administration, and the
current brain uptake levels were insufficient to assess the uptake
kinetics in vivo with for example SPECT imaging. (data not shown)
Additional experiments with untagged DTPA(
111In)-pa2H further
confirmed the current limitations as hardly any cerebral uptake
was observed with this labeling protocol. The increased brain
uptake for 99mTc-pa2H compared to DTPA(
111In)-pa2H may be
due to the slower blood clearance for
99mTc-pa2H. The observed
fast blood clearance and relatively high renal retention for the
VHH in this study is in line with previous reports [28,29], and
but sacrificed 24 hrs post-injection, showed similar results with pa2H-Alexa594 still nicely corresponding to the green labeling of the anti-Ab staining
within the right hemisphere (E).
doi:10.1371/journal.pone.0038284.g004
Figure 5. Immunofluorescence with VHH-Alexa594. Shown are the results of immunofluorescence staining with ni3A- and pa2H-Alexa594 on
cryosections of APP/PS1 murine and human AD/CAA brain tissue, including wildtype or healthy controls. Both VHH stain positive for CAA in all
sections (A, D, G, J). Only ni3A-Alexa594 stained negative for human parenchymal Ab (B), while pa2H stained positive for several types of
parenchymal Ab deposits (G, H, J, K) in both humans and mice. In either human of murine control tissue no such staining patterns were observed.(C,
F, I, L)
doi:10.1371/journal.pone.0038284.g005
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threshold of the glomerular membrane (,60 kDa) [30]. However,
in general, a short blood residential time effectively reduces the
blood-to-brain transfer.
In vivo studies with the BBB crossing VHH FC5 demonstrated
4%ID/g brain uptake, which is much higher than our findings
[31]. This discrepancy may be due to the lower dose that we used,
but several other factors may also play a part. For FC5 it is known
it uses receptor-mediated endocytosis via the a(2,3)-sialoglycopro-
tein [32]. For our VHH, in vitro active transport mechanisms are
involved, but the specific receptors are as yet unknown [12].
Possibly, the in vivo BBB passage may be limited by the availability
of these receptors in our mouse model.
To improve BBB penetration for the amyloid-targeting VHH,
one could increase the blood circulation time by multimerization
or by conjugating the VHH to an albumin-targeting moiety or
VHH [33,34]. An alternative approach would be to incorporate
the VHH into a BBB-targeting nanoparticle. Recently, several
nanoparticle carrier systems have been developed for brain
delivery of therapeutics that would also be suitable for loading
with VHH [35].
Diagnostic and therapeutic value of VHH
In general, VHH constitute many unique characteristics that
make them interesting tools for either diagnostics or therapeutics.
Compared to conventional monoclonal antibodies or Fab’, VHH
express a similar unique level of specificity and affinity, but
because of their single domain, production and modification is
relatively easy and cost-efficient [29].
Currently used amyloid-targeting ligands, like
11C-PiB recog-
nize amyloid plaques rather than Ab. In contrast, we already
showed that VHH may be more specific to a certain sub-types of
Ab accumulation [9]. Further selection may allow the in vivo
detection of the full range of Ab aggregates from oligomers to
dense core plaques to CAA.
Besides diagnostics, several VHH have shown their potential
therapeutic value in vitro, preventing aggregation of amyloid
fibrils, oligomeric forms of Ab and polyA-binding protein nuclear
1 [36–39]. In the latter case, even complete clearance of existing
aggregates was reported. Whether VHH evaluated in this study
possess similar abilities is currently under investigation. However,
within the data presented here, we observed that several Ab
plaques, as detected by their autofluorescence, could no longer be
seen two days after VHH application. (Figure 3) Whereas current
passive immunotherapies targeting Ab are hampered by unwanted
immunogenic side effects, repetitive administration of VHH has
shown to be non-immunogenic [4,40]. Furthermore, their selective
binding to different Ab species, like ni3A’s specific binding for
CAA, could shift Ab brain efflux in the favored direction, which
could be used to tailor anti-Ab therapy to further reduce therapy-
induced complications, e.g. CAA related microbleeds [4,5,41].
These initial in vivo studies to investigate whether Ab specific
VHH can be exploited as diagnostic tools show promising results
for further development. Although capable of strong specific
binding in vivo with low unspecific background binding and
favorable wash-out, issues regarding higher brain uptake and
clearance need to be addressed in the future.
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